BACKGROUND AND PURPOSE: Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the human vasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC(2)) and the type 1 corticotrophin releasing factor receptor (CRF(1)) has been examined. EXPERIMENTAL APPROACH: GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. Cell surface expression of RAMPs and GPCRs was examined by ELISA. Where there was evidence for interactions, agonist-stimulated cAMP production, Ca(2+) mobilization and GTPγS binding to G(s), G(i), G(12) and G(q) were examined. The ability of CRF to stimulate adrenal corticotrophic hormone release in Ramp2(+/-) mice was assessed. KEY RESULTS: The GLP-1 receptor failed to enhance the cell surface expression of any RAMP. VPAC(2) enhanced the cell surface expression of all three RAMPs. CRF(1) enhanced the cell surface expression of RAMP2; the cell surface expression of CRF(1) was also increased. There was no effect on agonist-stimulated cAMP production. However, there was enhanced G-protein coupling in a receptor and agonist-dependent manner. The CRF(1) : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF and urocortin 1 but not sauvagine. In Ramp2(+/-) mice, there was a loss of responsiveness to CRF. CONCLUSIONS AND IMPLICATIONS: The VPAC(2) and CRF(1) receptors interact with RAMPs. This modulates G-protein coupling in an agonist-specific manner. For CRF(1), coupling to RAMP2 may be of physiological significance.
BACKGROUND AND PURPOSE: Although it is established that the receptor activity modifying proteins (RAMPs) can interact with a number of GPCRs, little is known about the consequences of these interactions. Here the interaction of RAMPs with the glucagon-like peptide 1 receptor (GLP-1 receptor), the humanvasoactive intestinal polypeptide/pituitary AC-activating peptide 2 receptor (VPAC(2)) and the type 1 corticotrophin releasing factor receptor (CRF(1)) has been examined. EXPERIMENTAL APPROACH: GPCRs were co-transfected with RAMPs in HEK 293S and CHO-K1 cells. Cell surface expression of RAMPs and GPCRs was examined by ELISA. Where there was evidence for interactions, agonist-stimulated cAMP production, Ca(2+) mobilization and GTPγS binding to G(s), G(i), G(12) and G(q) were examined. The ability of CRF to stimulate adrenal corticotrophic hormone release in Ramp2(+/-) mice was assessed. KEY RESULTS: The GLP-1 receptor failed to enhance the cell surface expression of any RAMP. VPAC(2) enhanced the cell surface expression of all three RAMPs. CRF(1) enhanced the cell surface expression of RAMP2; the cell surface expression of CRF(1) was also increased. There was no effect on agonist-stimulated cAMP production. However, there was enhanced G-protein coupling in a receptor and agonist-dependent manner. The CRF(1) : RAMP2 complex resulted in enhanced elevation of intracellular calcium to CRF and urocortin 1 but not sauvagine. In Ramp2(+/-) mice, there was a loss of responsiveness to CRF. CONCLUSIONS AND IMPLICATIONS: The VPAC(2) and CRF(1) receptors interact with RAMPs. This modulates G-protein coupling in an agonist-specific manner. For CRF(1), coupling to RAMP2 may be of physiological significance.
Authors: David R Poyner; Patrick M Sexton; Ian Marshall; David M Smith; Remi Quirion; Walter Born; Roman Muff; Jan A Fischer; Steven M Foord Journal: Pharmacol Rev Date: 2002-06 Impact factor: 25.468
Authors: K R Oliver; S A Kane; C A Salvatore; J J Mallee; A M Kinsey; K S Koblan; N Keyvan-Fouladi; R P Heavens; A Wainwright; M Jacobson; I M Dickerson; R G Hill Journal: Eur J Neurosci Date: 2001-08 Impact factor: 3.386
Authors: Manami Tsutsumi; Thomas H Claus; Yin Liang; Yaxin Li; Ling Yang; Jian Zhu; Fernando Dela Cruz; Xianbu Peng; Hongxing Chen; Stephanie L Yung; Sarah Hamren; James N Livingston; Clark Q Pan Journal: Diabetes Date: 2002-05 Impact factor: 9.461
Authors: Arthur Christopoulos; George Christopoulos; Maria Morfis; Madhara Udawela; Marc Laburthe; Alain Couvineau; Kenji Kuwasako; Nanda Tilakaratne; Patrick M Sexton Journal: J Biol Chem Date: 2002-11-21 Impact factor: 5.157
Authors: Kevin R Oliver; Anna Wainwright; Lars Edvinsson; John D Pickard; Raymond G Hill Journal: J Cereb Blood Flow Metab Date: 2002-05 Impact factor: 6.200
Authors: Duncan I Mackie; Natalie R Nielsen; Matthew Harris; Smriti Singh; Reema B Davis; Danica Dy; Graham Ladds; Kathleen M Caron Journal: Proc Natl Acad Sci U S A Date: 2019-11-11 Impact factor: 11.205
Authors: Marilyn H Perrin; Laura A Tan; Joan M Vaughan; Kathy A Lewis; Cynthia J Donaldson; Charleen Miller; Judit Erchegyi; Jean E Rivier; Paul E Sawchenko Journal: J Pharmacol Exp Ther Date: 2015-03-03 Impact factor: 4.030